高脂血症与新型冠状病毒肺炎住院患者28天全因死亡率的关系

doi:10.24920/003866

Highlight

In a cohort of 10 945 hospitalized patients with COVID-19 from Hubei Province, China, Wu et al. found that hyperlipidemia was not significantly associated with an increased risk of 28-day all-cause COVID-19 mortality. This association remained non-significant even in the subgroup analyses on patients with cardiovascular diseases or diabetes. They also found that none of the specific lipid parameters, including TG, LDL-C, and HDL-C, was significantly correlated with 28-day all-cause mortality in this COVID-19 cohort.

Abstract

Objective This study aimed to determine the association of hyperlipidemia with clinical endpoints among hospitalized patients with COVID-19, especially those with pre-existing cardiovascular diseases (CVDs) and diabetes.

Methods This multicenter retrospective cohort study included all patients who were hospitalized due to COVID-19 from 21 hospitals in Hubei province, China between December 31, 2019 and April 21, 2020. Patients who were aged < 18 or ≥ 85 years old, in pregnancy, with acute lethal organ injury (e.g., acute myocardial infarction, severe acute pancreatitis, acute stroke), hypothyroidism, malignant diseases, severe malnutrition, and those with normal lipid profile under lipid-lowering medicines (e.g., statin, niacin, fenofibrate, gemfibrozil, and ezetimibe) were excluded. Propensity score matching (PSM) analysis at 1:1 ratio was performed to minimize baseline differences between patient groups of hyperlipidemia and non-hyperlipidemia. PSM analyses with the same strategies were further conducted for the parameters of hyperlipidemia in patients with increased triglyceride (TG), increased low-density lipoprotein cholesterol (LDL-C), and decreased high-density lipoprotein cholesterol (HDL-C). Mixed-effect Cox model analysis was performed to investigate the associations of the 28-days all-cause deaths of COVID-19 patients with hyperlipidemia and the abnormalities of lipid parameters. The results were verified in male, female patients, and in patients with pre-existing CVDs and type 2 diabetes.

Results Of 10 945 inpatients confirmed as COVID-19, there were 9822 inpatients included in the study, comprising 3513 (35.8%) cases without hyperlipidemia and 6309 (64.2%) cases with hyperlipidemia. Based on a mixed-effect Cox model after PSM at 1:1 ratio, hyperlipidemia was not associated with increased or decreased 28-day all-cause death [adjusted hazard ratio (HR), 1.17 (95% CI, 0.95-1.44), P =0.151]. We found that the parameters of hyperlipidemia were not associated with the risk of 28-day all-cause mortality [adjusted HR, 1.23 (95% CI, 0.98-1.55), P = 0.075 in TG increase group; 0.78 (95% CI, 0.57-1.07), P = 0.123 in LDL-C increase group; and 1.12 (95% CI, 0.9-1.39), P = 0.299 in HDL-C decrease group, respectively]. Hyperlipidemia was also not significantly associated with the increased mortality of COVID-19 in patients accompanied with CVDs or type 2 diabetes, and in both male and female cohorts.

Conclusion Our study support that the imbalanced lipid profile is not significantly associated with the 28-day all-cause mortality of COVID-19 patients, even in those accompanied with CVDs or diabetes. Similar results were also obtained in subgroup analyses of abnormal lipid parameters. Therefore, hyperlipidemia might be not a major causative factor for poor outcome of COVID-19, which provides guidance for the intervention of inpatients during the epidemic of COVID-19.

Key words: coronavirus disease 2019 (COVID-19), lipid disorder, mortality, cardiovascular diseases, diabetes

Funding: This work was supported by grants from National Key R&D Program of China(2016YFF0101500);the National Natural Science Foundation of China(81970364);the National Natural Science Foundation of China(81770053)

Bin Wu,Jianghua Zhou,Wenxin Wang,Huilin Yang,Meng Xia,Binghong Zhang,Zhigang She,Hongliang Li. Association Analysis of Hyperlipidemia with the 28-Day All-Cause Mortality of COVID-19 in Hospitalized Patients[J].Chinese Medical Sciences Journal, 2021, 36(1): 17-26.

Figures/Tables 4

Figure 1.

Table 1

Baseline characteristics of the study cohort before and after matching"

Characteristics	Study cohort			Cohort after matching (1:1)^b
Characteristics	Hyperlipidemia^a (n=6309)	Normal (n=3513)	SD	Hyperlipidemia ^a (n=3506)	Normal (n=3506)	SD
Age [years, median (IQR)]	59(48-68)	59(45-68)	0.083	58(47-67)	59(45-68)	-0.001
Gender-male [n (%)]	3387(53.69)	1450(41.28)	0.250	1597(45.55)	1450(41.36)	0.085
Heart rate [bpm, median (IQR)]	85(78-97)	84(78-96)	0.049	85(78-96)	84(78-96)	0.005
Respiratory [bpm, median(IQR)]	20(19-21)	20(19-21)	0.104	20(19-21)	20(19-21)	-0.018
SBP [mmHg, median (IQR)]	129(120-141)	128(118-139)	0.087	128(119-140)	128(118-139)	0.025
DBP [mmHg, median (IQR)]	80(72-88)	79(72-86)	0.101	79(72-87)	79(72-86)	0.038
SpO₂ [%, median(IQR)]	97(95-98)	97(96-98)	-0.06	98(96-98)	97(96-98)	0.024
Comorbidities on admission [n (%)]
Chronic obstructive pulmonary disease	67(1.06)	47(1.34)	-0.025	45(1.28)	45(1.28)	0.000
Diabetes	1095(17.36)	408(11.61)	0.164	386(11.01)	408(11.64)	-0.020
Heart failure	40(0.63)	23(0.65)	-0.003	20(0.57)	23(0.66)	-0.011
Coronary heart disease	603(9.56)	195(5.55)	0.152	204(5.82)	195(5.56)	0.011
Cerebrovascular diseases	196(3.11)	81(2.31)	0.049	89(2.54)	81(2.31)	0.015
Chronic liver disease	151(2.39)	76(2.16)	0.015	75(2.14)	76(2.17)	-0.002
Chronic renal diseases	266(4.22)	103(2.93)	0.002	112(3.19)	103(2.94)	0.015
Medications [n (%)]
Insulin	975(15.45)	320(9.11)	0.194	332(9.47)	320(9.13)	0.012
Oral hypoglycemic drugs	1352(21.43)	456(12.98)	0.225	474(13.52)	456(13.01)	0.015
non-ACEI/ARB antihypertensive drug	1907(30.23)	873(24.85)	0.121	814(23.22)	872(24.87)	-0.039
ACEI/ARB	628(9.95)	233(6.63)	0.121	215(6.13)	233(6.65)	-0.021
Antiplatelet	533(8.45)	110(3.13)	0.229	89(2.54)	110(3.14)	-0.036
Chest CT on admission [n (%)]
Bilateral lesions	5154(87.05)	2808(83.60)	0.098	2718(83.35)	2807(83.74)	-0.011
Lab tests on admission [n (%), or median(IQR)]
Leukocyte count > 9.5×10⁹/L	697(11.08)	270(7.71)	0.116	313(8.98)	270(7.73)	0.045
Neutrophil count > 6.3×10⁹/L	1062(16.89)	412(11.77)	0.146	455(13.05)	412(11.80)	0.038
Lymphocyte< 1.1×10⁹/L	2595(41.26)	1400(40.00)	0.026	1405(40.28)	1394(39.91)	0.008
RBC < 3.5×10¹²/L (female) or 4.0×10¹²/L (male)	2568(40.83)	1579(45.14)	-0.087	1441(41.32)	1574(45.09)	-0.076
CRP > ULN ^c	2103(52.65)	821(46.10)	0.131	1257(51.52)	819(46.11)	0.108
PCT > ULN ^c	2479(45.06)	1021(34.95)	0.207	954(31.39)	1020(34.99)	-0.076
ALT > 40 U/L	1679(26.63)	640(18.23)	0.202	611(17.45)	640(18.27)	-0.021
eGFR value (mL/min)	103.57 (87.61-120.50)	105.30 (89.21-122.61)	-0.073	107.34 (91.14-125.22)	105.29 (89.21-122.55)	0.043
D-dimer > ULN ^c	3024(52.06)	1351(42.26)	0.197	1479(46.88)	1351(42.32)	0.092
cTnI > ULN^c	446(10.96)	160(7.35)	0.125	153(7.65)	160(7.36)	0.013

Table 1

Table 2

Table 3

References 38.

1.	Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin Ⅱ receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020; 126(12):1671-81. doi: 10.1161/CIRCRESAHA.120.317134. doi: 10.1161/CIRCRESAHA.120.317134 pmid: 32302265
2.	Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020;31(6):1068-77.e3. doi: 10.1016/j.cmet.2020.04.021. doi: 10.1016/j.cmet.2020.04.021 pmid: 32369736
3.	Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5(7):811-8. doi: 10.1001/jamacardio.2020.1017. doi: 10.1001/jamacardio.2020.1017 pmid: 32219356
4.	Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020; 8(6):546-50. doi: 10.1016/S2213-8587(20)30152-2. doi: 10.1016/S2213-8587(20)30152-2 pmid: 32334646
5.	Ni WQ, Liu XL, Zhuo ZP, et al. Serum lipids and associated factors of dyslipidemia in the adult population in Shenzhen. Lipids Health Dis 2015; 14(1):1-11. doi: 10.1186/s12944-015-0073-7.
6.	Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity is associated with higher in-hospital mortality in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism 2020; 108:154262. doi: 10.1016/j.metabol.2020.154262. doi: 10.1016/j.metabol.2020.154262 pmid: 32422233
7.	Abu-Farha M, Thanaraj TA, Qaddoumi MG, et al. The role of lipid metabolism in COVID-19 virus infection and as a drug target. Int J Mol Sci 2020; 21(10):3544. doi: 10.3390/ijms21103544.
8.	Tanaka S, Labreuche J, Drumez E, et al. Low HDL levels in sepsis versus trauma patients in intensive care unit. Ann Intensive Care 2017; 7(1):4-11. doi: 10.1186/s13613-017-0284-3. doi: 10.1186/s13613-016-0231-8 pmid: 28050897
9.	Peñarrubia L, Ruiz M, Porco R, et al. Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak. Int J Infect Dis 2020; 97:225-9. doi: 10.1016/j.ijid.2020.06.027.
10.	Official website of the National Health Commission of People’s Republic of China. The prevention and control guideline for novel coronavirus pneumonia (5th edition). .
11.	Joint committee issued Chinese guideline for the management of dyslipidemia. 2016 Chinese guideline for the management of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi 2016; 44(10):833-53. Chinese. doi: 10.3760/cma.j.issn.0253-3758.2016.10.005.
12.	Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. doi: 10.1016/j.atherosclerosis.2019.08.014 pmid: 31591002
13.	Chinese Diabetes Society; National Office for Primary Diabetes Care. National guidelines for the prevention and control of diabetes in primary care( 2018). Zhonghua nei ke za zhi 2018; 57(12):885-93. Chinese. doi: 10.3760/cma.j.issn.0578-1426.2018.12.003.
14.	Jakubowski KP, Cundiff JM, Matthews KA. Cumulative childhood adversity and adult cardiometabolic disease: A meta-analysis. Heal Psychol 2018; 37(8):701-15. doi: 10.1037/hea0000637.
15.	Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020; 20(6):363-74. doi: 10.1038/s41577-020-0311-8.
16.	Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 2020; 20(5):269-70. doi: 10.1038/s41577-020-0308-3. pmid: 32273594
17.	Touyz RM, Li H, Delles C. ACE2 the Janus-faced protein-from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19. Clin Sci 2020; 134(7):747-50. doi: 10.1042/CS20200363.
18.	Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ 2020; 368(m1091):1-14. doi: 10.1136/bmj.m1091.
19.	Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 2020; 323(20):2052-9. doi: 10.1001/jama.2020.6775. pmid: 32320003
20.	Shao B, Heinecke JW. HDL, lipid peroxidation, and atherosclerosis. J Lipid Res 2009; 50(4):599-601. doi: 10.1194/jlr.E900001-JLR200. doi: 10.1194/jlr.E900001-JLR200 pmid: 19141435
21.	Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352(16):1685-95. doi: 10.1056/NEJMra043430. pmid: 15843671
22.	Steinberg D. An interpretive history of the cholesterol controversy, part III: Mechanistically defining the role of hyperlipidemia. J Lipid Res 2005; 46(10):2037-51. doi: 10.1194/jlr.R500010-JLR200. doi: 10.1194/jlr.R500010-JLR200 pmid: 15995167
23.	Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3. doi: 10.1016/S0140-6736(20)30566-3 pmid: 32171076
24.	Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8(5):475-81. doi: 10.1016/S2213-2600(20)30079-5. doi: 10.1016/S2213-2600(20)30079-5 pmid: 32105632
25.	Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014; 370(23):2201-10. doi: 10.1056/nejmoa1403086.
26.	Truwit JD, Bernard GR, Steingrub J, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 2014; 370(23):2191-200. doi: 10.1056/NEJMoa1401520. doi: 10.1056/NEJMoa1401520 pmid: 24835849
27.	Zhang XJ, Qin JJ, Cheng X, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab 2020; 32(2):176- 87. e4. doi: 10.1016/j.cmet.2020.06.015.
28.	Liu G, Zhang S, Mao Z, et al. Clinical significance of nutritional risk screening for older adult patients with COVID-19. Eur J Clin Nutr 2020; 74(6):876-83. doi: 10.1038/s41430-020-0659-7.
29.	Deniz O, Gumus S, Yaman H, et al. Serum total cholesterol, HDL-C and LDL-C concentrations significantly correlate with the radiological extent of disease and the degree of smear positivity in patients with pulmonary tuberculosis. Clin Biochem 2007; 40(3-4):162-6. doi: 10.1016/j.clinbiochem.2006.10.015. doi: 10.1016/j.clinbiochem.2006.10.015 pmid: 17217941
30.	Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin Ⅱ receptors. Hypertension 2004; 43(5):970-6. doi: 10.1161/01.HYP.0000124667.34652.1a.
31.	Dijkman R, Jebbink MF, Deijs M, et al. Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63. J Gen Virol 2012; 93(Pt 9):1924-9. doi: 10.1099/vir.0.043919-0.
32.	Putnam K, Shoemaker R, Yiannikouris F, et al. The renin-angiotensin system: A target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J
	Physiol Hear Circ Physiol 2012; 302(6):H1219-30. doi: 10.1152/ajpheart.00796.2011.
33.	Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019; 393(10170):407-15. doi: 10.1016/S0140-6736(18)31942-1. pmid: 30712900
34.	Lemmers RFH, van Hoek M, Lieverse AG, et al. The anti-inflammatory function of high-density lipoprotein in type II diabetes: A systematic review. J Clin Lipidol 2017; 11(3):712-24. doi: 10.1016/j.jacl.2017.03. doi: 10.1016/j.jacl.2017.03.013 pmid: 28442299
	013. doi: 10.1016/j.jacl.2017.03.013 pmid: 28442299
35.	Hui N, Barter PJ, Ong KL, et al. Altered HDL metabolism in metabolic disorders: Insights into the therapeutic potential of HDL. Clin Sci 2019; 133(21):2221-35. doi: 10.1042/CS20190873.
36.	Wei X, Zeng W, Su J, et al. Hypolipidemia is associated with the severity of COVID-19. J Clin Lipidol 2020; 14(3):297-304. doi: 10.1016/j.jacl.2020.04.008. doi: 10.1016/j.jacl.2020.04.008 pmid: 32430154
37.	Guirgis FW, Donnelly JP, Dodani S, et al. Cholesterol levels and long-term rates of community-acquired sepsis. Crit Care 2016; 20(1):1-12. doi: 10.1186/s13054-016-1579-8.
38.	Cirstea M, Walley KR, Russell JA, et al. Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis. J Crit Care 2017; 38:289-94. doi: 10.1016/j.jcrc.2016.11.041.

Categories	Number of patients (n)	Deaths (n)	Adjusted HR (95% CI)	P value ^a
All patients of matched cohort ^b
Hyperlipidemia group vs. non-hyperlipidemia group	3506 vs. 3506	231 vs. 193	1.17 (0.95, 1.44)	0.151
TG ≥1.7 mmol/L group vs. TG<1.7 mmol/L group	2409 vs. 2409	180 vs. 137	1.23 (0.98, 1.55)	0.075
LDL-C ≥3 mmol/L group vs. LDL-C<3 mmol/L group	2083 vs. 2083	67 vs. 95	0.78 (0.57, 1.07)	0.123
HDL-C <1.0 mmol/L group vs. HDL-C ≥1.0 mmol/L group	2855 vs. 2855	213 vs. 157	1.12 (0.90, 1.39)	0.299
Male patients in matched cohort ^c
Hyperlipidemia group vs. non-hyperlipidemia group	1449 vs. 1449	135 vs. 112	1.24 (0.91, 1.70)	0.176
TG ≥1.7 mmol/L group vs. TG<1.7 mmol/L group	1145 vs. 1145	114 vs. 81	1.23 (0.92, 1.66)	0.170
LDL-C ≥3 mmol/L group vs. LDL-C<3 mmol/L group	988 vs. 988	43 vs. 46	1.00 (0.65, 1.52)	0.983
HDL-C <1.0 mmol/L group vs. HDL-C ≥1.0 mmol/L group	1499 vs. 1499	131 vs. 86	1.27 (0.94, 1.72)	0.113
Female patients in matched cohort ^d
Hyperlipidemia group vs. non-hyperlipidemia group	2014 vs. 2014	92 vs. 81	0.91 (0.66, 1.25)	0.547
TG ≥1.7 mmol/L group vs. TG<1.7 mmol/L group	1233 vs. 1233	62 vs. 50	1.14 (0.78, 1.66)	0.509
LDL-C ≥3 mmol/L group vs. LDL-C<3 mmol/L group	1099 vs. 1099	24 vs. 33	0.82 (0.48, 1.39)	0.456
HDL-C <1.0 mmol/L group vs. HDL-C ≥1.0 mmol/L group	1326 vs. 1326	79 vs. 66	1.00 (0.71, 1.40)	0.993

Categories	Number of Patients (n)	Deaths (n)	Adjusted HR (95% CI)	P value ^a
Cardiovascular diseases ^b
Hyperlipidemia group vs. non-hyperlipidemia group	1242 vs. 1242	128 vs. 114	0.96 (0.73,1.26)	0.765
TG ≥1.7 mmol/L group vs. TG<1.7 mmol/L group	1004 vs. 1004	115 vs. 81	1.19 (0.88,1.60)	0.253
LDL-C ≥3 mmol/L group vs. LDL-C<3 mmol/L group	814 vs. 814	42 vs. 59	0.78 (0.52,1.17)	0.235
HDL-C <1.0 mmol/L group vs. HDL-C ≥1.0 mmol/L group	1131 vs. 1131	124 vs. 90	1.00 (0.75,1.33)	0.991
Type 2 diabetes ^c
Hyperlipidemia group vs. non-hyperlipidemia group	473 vs. 473	52 vs. 54	0.74 (0.49,1.13)	0.164
TG ≥1.7 mmol/L group vs. TG<1.7 mmol/L group	515 vs. 515	56 vs. 40	1.07 (0.70,1.64)	0.752
LDL-C ≥3 mmol/L group vs. LDL-C<3 mmol/L group	364 vs. 364	20 vs. 29	0.72 (0.40,1.30)	0.279
HDL-C <1.0 mmol/L group vs. HDL-C ≥1.0 mmol/L group	492 vs. 492	56 vs. 43	1.17 (0.76,1.81)	0.468

[1]	Yu Gu,Ting Zhang,Min Peng,Juhong Shi. Characteristics and Prognosis of Microscopic Polyangiitis Patients with Diffuse Alveolar Hemorrhage and Interstitial Lung Disease [J]. Chinese Medical Sciences Journal, 2022, 37(4): 293-302.
[2]	Zihan Chen, Zhou Zhao, Chuiwen Deng, Naishi Li. Association between Air Pollution and Type 2 Diabetes Mellitus in Developing Countries: A Systematic Review and Meta-Analysis [J]. Chinese Medical Sciences Journal, 2022, 37(3): 218-227.
[3]	Tieli Li, Haixuan Ding, Xinlan Zhao, Juan Luo, Kai Chen, Zhuo Tang, Lingyun Huang, Langbo Li, Li Yang. A Case Report of MODY₃ Combined with Intestinal Neuroendocrine Tumor [J]. Chinese Medical Sciences Journal, 2022, 37(2): 167-170.
[4]	Kunrong Wu, Shufang Zhang, Ziwan Guan, Xiaoli Li, Rui Li, Ying Yin, Yan Li. Methylenetetrahydrofolate Reductase Gene Polymorphism C677T is Associated with Increased Risk of Coronary Heart Disease in Chinese Type 2 Diabetic Patients [J]. Chinese Medical Sciences Journal, 2021, 36(2): 103-109.
[5]	Honglin Zu,Likun Hou,Hongwei Liu,Yuanbo Zhan,Ju He. Identify Candidate Genes in the Interaction between Abdominal Aortic Aneurysm and Type 2 Diabetes Mellitus by Using Biomedical Discovery Support System [J]. Chinese Medical Sciences Journal, 2021, 36(1): 50-56.
[6]	Lin Ye, Wang Zhenlian, Yan Min, Zhu Feiyu, Duan Ye, Sun Zhiqin. Effect of Trimetazidine on Diabetic Patients with Coronary Heart Diseases: A Meta-Analysis of Randomized, Controlled Trials [J]. Chinese Medical Sciences Journal, 2020, 35(3): 226-238.
[7]	Zhu Weihua,Xie Wenyong,Zhang Zhedong,Li Shu,Zhang Dafang,Liu Yijun,Zhu Jiye,Leng Xisheng. Postoperative Complications and Survival Analysis of Surgical Resection for Hilar Cholangiocarcinoma: A Retrospective Study of Fifty-Nine Consecutive Patients [J]. Chinese Medical Sciences Journal, 2020, 35(2): 157-169.
[8]	Yin Ying, Li Rui, Li Xiaoli, Wu Kunrong, Li Ling, Xu Yuedong, Liao Lin, Yang Rui, Li Yan. Association Between Homocysteine Level and Methylenetetrahydrofolate Reductase Gene Polymorphisms in Type 2 Diabetes Accompanied by Dyslipidemia [J]. Chinese Medical Sciences Journal, 2020, 35(1): 85-91.
[9]	Chen Qiang, Zhang Liwei, Huang Dangsheng, Zhang Chunhong, Wang Qiushuang, Shen Dong, Xiong Minjun, Yang Feifei. Five-year Clinical Outcomes of CAD Patients Complicated with Diabetes after StentBoost-optimized Percutaneous Coronary Intervention [J]. Chinese Medical Sciences Journal, 2019, 34(3): 177-183.
[10]	Dai Yulan,Zhu Chengzhang,Shan Xi,Cheng Zhenzhen,Zou Beiji. A Survey on Intelligent Screening for Diabetic Retinopathy [J]. Chinese Medical Sciences Journal, 2019, 34(2): 120-132.
[11]	Chen Zhiye, Zang Xiujuan, Liu Mengqi, Liu Mengyu, Li Jinfeng, Gu Zhaoyan, Ma Lin. Abnormal Alterations of Cortical Thickness in 16 Patients with Type 2 Diabetes Mellitus: A Pilot MRI Study^△ [J]. Chinese Medical Sciences Journal, 2017, 32(2): 75-82.
[12]	Du Junhui, Li Rong. Can Fundus Fluorescein Angiography be Performed for Diabetic Patients on Oral Metformin?^△ [J]. Chinese Medical Sciences Journal, 2017, 32(2): 119-122.
[13]	Yang Yingying, Pan Hui, Wang Bo, Chen Shi, Zhu Huijuan. Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials [J]. Chinese Medical Sciences Journal, 2017, 32(1): 22-27.
[14]	Jing Yang, Mei-cen Zhou, Kai Feng, Ou Wang, Hua-bing Zhang, Wei Li, Fan Ping, Jing Yang, Yu-xiu Li. Clinical Characteristics of 261 Cases of Hospitalized Patients with Type 1 Diabetes Mellitus [J]. Chinese Medical Sciences Journal, 2016, 31(2): 69-75.
[15]	Ying Fan, Shan-xiao Zhang, Meng Ren, Li-feng Hong, Xiao-ni Yan. Impact of 1, 25-(OH)₂D₃ on Left Ventricular Hypertrophy in Type 2 Diabetic Rats [J]. Chinese Medical Sciences Journal, 2015, 30(2): 114-120.

Early edition

Current issue

Archive

Specialties & Topics

Author center

Reviewer center

Association Analysis of Hyperlipidemia with the 28-Day All-Cause Mortality of COVID-19 in Hospitalized Patients

RichHTML

PDF (PC)

Supplement

Knowledge

Highlight

Abstract

Cite this article

share this article

Figures/Tables 4

References 38.

Related Articles 15

Metrics

Recommended 10